TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03208036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS
Description: 1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation
Description: Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Bridging Group
Description: Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging Group
Description: Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
Study: NCT01702272

Intervention type: DEVICE
Intervention: Procleix Dengue Virus Assay
Description: in vitro diagnostic assay
Study: NCT01511705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Hydrochloride
Description: Ondansetron Hydrochloride Tablets 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: Zofran Tablets 8 mg
Study: NCT03814772

Intervention type: PROCEDURE
Intervention: Liver transplant
Description: blood transfusion
Study: NCT05458570

Intervention type: OTHER
Intervention: Breast Cancer positive patients
Study: NCT04672785

Intervention type: BEHAVIORAL
Intervention: SF36 questionary
Description: patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
Study: NCT02613234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathode tDCS
Description: At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cathode tDCS
Description: At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA).
Study: NCT00350103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 929
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 929
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use
Study: NCT01983189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: 1 hz transcranial magnetic stimulation
Study: NCT05863728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery assisted group
Description: apicectomy will be done using the Piezosurgery device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trephine Bur assisted group
Description: apicectomy will be done using the trephine burs
Study: NCT05366036

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT02433574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Stereotactic body radiation (SBRT)
Description: Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments.
Study: NCT03598959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: orally 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: orally 20 mg twice weekly
Study: NCT01262027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: 500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
Study: NCT04041453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Study: NCT03479762

Intervention type: DRUG
Intervention: Liraglutide
Description: No treatment given
Study: NCT00929747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric
Description: Unilateral implantation of the AcrySof IQ Toric IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal Relaxing Incision
Description: Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
Study: NCT00490724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (1+0.01)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (2+0.005)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesritide (2+0.01)
Description: Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
Study: NCT00080678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study: NCT02217956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT00910234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin (rhEpo)
Description: rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human erythropoietin (rhEpo)
Description: rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study: NCT03804970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash rewards for the fellow up
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cash rewards for the fellow up
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study: NCT00910234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study: NCT03804970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Showing retinal photos to participants
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Showing retinal photos to participants
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders for participants and their family
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study: NCT01510405

Intervention type: OTHER
Intervention: Tissue Collection
Description: Tissue sample collection
Study: NCT02873975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2606368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2606368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2606368
Study: NCT00646724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cotransplantation of islet and mesenchymal stem cell
Description: islet of allograft and MSCs of autograft
Study: NCT03804970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders for participants and their family
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Watching brief video and basic explanation for disease
Description: This basic explanation will be offered by professional doctors or nurses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Having the Diabetic Club
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Having the Diabetic Club
Description: This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
Study: NCT00794664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mipomersen
Description: 200 mg (1 mL), weekly subcutaneous injections for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL weekly subcutaneous injections for 26 weeks
Study: NCT00921323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-setting group
Description: This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
Study: NCT04268927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH ant/letrozole
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH ant
Description: Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study: NCT01998100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
Study: NCT02998580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFR followed by HFL
Description: Magventure Cool B70 Coil with RX100 Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS followed by iTBS
Description: Magventure Cool B70 Coil with RX100 Stimulator
Study: NCT00733187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg
Study: NCT02819557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: White to off-white powder for oral suspension.
Study: NCT04668404

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonoclot
Description: Sonoclot machine
Study: NCT00921323

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will be advised to continue to be physically active and record daily steps
Study: NCT03504800

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
Study: NCT01450488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 3 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 6 mg/kg/day
Study: NCT01270477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Description: Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
Study: NCT03532737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Adding PD-1 inhibitor to the standard of care
Study: NCT04198935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Span Health Mobile Application
Description: A 12 week structured diabetes education program for type 2 diabetes delivered through a mobile application. The application also allows for interaction with a registered nutritionist via text messaging.
Study: NCT01589315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focal ECT
Description: FEAST, ECT, unidirectional stimulation
Study: NCT01850641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study: NCT03999255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined respiratory support (CRS)
Description: combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
Study: NCT00677898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered computerized tool
Description: A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written educational materials
Description: Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
Study: NCT02344823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: per oral intake of 10mg Vardenafil once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: per oral intake of 10mg Vardenafil once daily
Study: NCT04787887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abcertin
Description: 60IU/kg Single Intravenous Administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abcertin
Description: 60IU/kg Single Intravenous Administration